BRISTOL MYERS SQUIBB CO
CELG-RIDrugs in Pipeline
184
Phase 3 Programs
96
Upcoming Catalysts
12
Next Catalyst
Mar 29, 2026
25dMarket Overview
Stock performance and key metrics
12 upcoming, 0 past
Temozolomide
Brain Cancer
Atazanavir/Ritonavir
HIV
Carboplatin
Pediatric Solid Tumors
Elotuzumab
Multiple Myeloma
Adalimumab
Rheumatoid Arthritis
Mezigdomide
Relapsed or Refractory Multiple Myeloma
Enoxaparin
Deep Vein Thrombosis
Epoetin Alfa
Myelodysplastic Syndromes
Pegylated-Interferon-lambda
Hepatitis C Virus
Apixaban
Lymphoma
dasatinib
Myeloid Leukemia, Chronic, Accelerated Phase
Paclitaxel
Breast Cancer
Muraglitazar
Metabolics Diabetes Nos
Atazanavir + Ritonavir
Human Immunodeficiency Virus (HIV) Infections
Sorafenib
Hepatocellular Carcinoma
SAR302503
Hematopoietic Neoplasm
Irbesartan monotherapy
Hypertension
Atazanavir Sulphate
HIV
Pomalidomide
Multiple Myeloma
Asunaprevir (ASV)
Hepatitis C Virus
Antidepressant + Aripiprazole
Major Depressive Disorder
Asunaprevir
Hepatitis C
DCV
Hepatitis C
Relatlimab
Advanced Gastric Cancer
Daclatasvir
Hepatitis C Infection
Oral Azacitidine
Myelodysplastic Syndromes
Atazanavir (immediate switch)
HIV Infections
Cabozantinib
Renal Cell Carcinoma
Atazanavir
HIV Infections
Lamivudine/Zidovudine
HIV Infections
Peg-interferon Alfa-2a
Hepatitis C Virus
Gemcitabine
Stage IV or Recurrent Non-Small Cell Lung Cancer
Iza-bren
Urothelial Cancer
Bempegaldesleukin
Bladder Cancer
Pemetrexed
Mesothelioma, Malignant
Fluorouracil
Various Advanced Cancer
Xanomeline/Trospium Chloride Capsule
Alzheimer Disease
Iberdomide
Multiple Myeloma
Sunitinib
Advanced Renal Cell Carcinoma
Deucravacitinib
Psoriatic Arthritis
Docetaxel
Non-Small Cell Lung Cancer
Double-blind Abatacept
Rheumatoid Arthritis
BMS-986165
Psoriasis
KarXT
Alzheimer Disease
BMS-790052 (NS5A Replication Complex Inhibitor)
Hepatitis C
DCV 3DAA
Hepatitis C Virus Infection
Atazanavir + ritonavir + tenofovir + nucleoside
HIV Infections
BMS-986504
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Rheumatoid Arthritis
BMS-936558
Unresectable or Metastatic Melanoma
Videx EC
HIV Infections
Etoposide
Small Cell Lung Carcinoma
Apremilast
Psoriatic Arthritis
Ustekinumab
Plaque Psoriasis
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Rheumatoid Arthritis
Tenofovir
Chronic Hepatitis B
Oxaliplatin
Colorectal Cancer
Imatinib
Chronic Myeloid Leukemia
Telaprevir
Hepatitis C
MDX-010 (anti-CTLA4) monoclonal antibody
Melanoma
Paclitaxel and carboplatin
Carcinoma, Non-Small-Cell Lung
Pegylated interferon lambda (pegIFNλ)
Hepatitis C Virus (HCV)
Prednisone
Prostate Cancer
Irbesartan
Atrial Fibrillation
stavudine, efavirenz, lamivudine
HIV Infections
Ribavirin
Hepatitis C
Methotrexate
Rheumatoid Arthritis
DCV/ASV/BMS-791325
Hepatitis C Virus
Subcutaneous (SC) Abatacept
Rheumatoid Arthritis (RA)
Dacarbazine
Melanoma
Methotrexate (MTX)
Rheumatoid Arthritis (RA)
Irbesartan/HCTZ
Hypertension
Peginterferon Lambda-1a
Hepatitis C Virus (HCV)
atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
HIV Infections
Lenalidomide
Multiple Myeloma
Bortezomib
Multiple Myeloma
Nelfinavir mesylate
HIV Infections
Tanespimycin
Advanced Malignancies
Brivanib
Hepato Cellular Carcinoma (HCC)
BMS-986278
Idiopathic Pulmonary Fibrosis
Sofosbuvir
Hepatitis C
Sorivudine
HIV Infections
KarX-EC
Alzheimer's Disease
warfarin
Venous Thrombosis
Adefovir
Hepatitis B, Chronic
Cyclosporin A
Renal Transplantation
Luspatercept
Myelodysplastic Syndromes
Acetylsalicylic acid
Atrial Fibrillation
abatacept (ABA)
Ulcerative Colitis
pegIFNα-2b
Hepatitis C Virus Infection
Cetuximab
Squamous Cell Carcinoma of the Head and Neck
Stavudine
HIV Infections
Mavacamten
Cardiomyopathy, Hypertrophic
Abatacept
Rheumatoid Arthritis
Entecavir
Hepatitis B, Chronic
Cisplatin
Non Small Cell Lung Cancer
Vitamin K Antagonist (VKA)
Thrombosis
brivanib (active)
Hepatocellular Carcinoma (HCC)
Letrozole
Metastatic Breast Cancer
CXL-1020
Heart Failure
Abatacept (BMS-188667)
Rheumatoid Arthritis
BMS-986263
Hepatic Cirrhosis
BMS-986490
Advanced Solid Tumors
INX-08189 50 mg QD X 5 days
Healthy
MYK-491
Heart Failure With Reduced Ejection Fraction
Anti-CD137 (4-1BB) (BMS-663513)
Melanoma
Sirolimus
Disorder Related to Renal Transplantation
BMS-914392
Atrial Fibrillation
Erlotinib
Non Small Cell Lung Cancer
BMS-650032
Hepatitis C Virus
bendamustine
Hodgkin Disease
nab-Paclitaxel
Non-Small Cell Lung Cancer
PSI-7977
Chronic Hepatitis C
Pegylated Interferon Lambda
Hepatitis C
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
HIV Infections
200 mg INX-08189 Fasted
Hepatitis C
BMS-986369
Relapsed or Refractory T-cell Lymphomas
unfractionated heparin (UFH)
Antithrombotic
Peginterferon alpha-2a
Hepatitis C Infection
MORAb-202
Neoplasms, Ovarian
BMS-986523
Advanced Solid Malignancies
BMS-986259
Acute Decompensated Heart Failure
BMS-986036
Non-Alcoholic Steatohepatitis
branebrutinib
Autoimmune Disorder
Exemestane + Dasatinib
Breast Cancer
BMS-823778
Dyslipidemia
Lirilumab
Non-Hodgkin's Lymphoma
vinflunine
Transitional Cell Carcinoma
Dasatinib 100 mg
Breast Cancer
Duloxetine
Depression
MDX-1100
Rheumatoid Arthritis
Fulvestrant
Advanced Breast Cancer
BMS-986213
Advanced Solid Tumors
Trametinib
Cancer
Fedratinib
Primary Myelofibrosis
BMS-986158
Myelofibrosis
BMS-986231
Cardiac Failure
Megestrol acetate
Anorexia
BMS-986020
Idiopathic Pulmonary Fibrosis
Opdivo
Renal Cell Carcinoma
BMS-830216
Obesity
carboplatin + irinotecan
Neoplasms
BMS-986340
Cervical Cancer
Anastrozole
Breast Cancer
BMS-986446
Alzheimer Disease, Early Onset
BMS-582949
Vascular Diseases
Cobimetinib
Microsatellite Unstable Colorectal Cancer
MDX-010
Breast Cancer
BMS-986004 75 mg IV
Immune Thrombocytopenic Purpura
SAR302503 (TG101348)
Myelofibrosis
Vemurafenib
Melanoma
HNO Donor
Heart Failure
BMS-986435
Heart Failure
Afimetoran
Systemic Lupus Erythematosus
BMS-986205
Advanced Cancer
ixabepilone
Esophageal Cancer
KOS-1584
Non-Small Cell Lung Cancer
Thalidomide
Relapsed and/or Refractory Multiple Myeloma
INX-08189 50 mg
Healthy
Cyclophosphamide
Breast Cancer
BMS-790052
Hepatitis C Infection
BMS-986142
Rheumatoid Arthritis
CC-92480
Multiple Myeloma
BMS-770767
Diabetes Type 2
Pegylated-interferon alfa-2a
Chronic Hepatitis C
Cabiralizumab
Advanced Pancreatic Cancer
CXL-1427
Heart Failure
Peginterferon α-2a
Hepatitis C
Aurexis®
Staphylococcus Aureus Bacteremia
BMS-986507
Lung Cancer
Pegylated interferon alfa-2a
Hepatitis C Virus
BMS-954561
Diabetic Peripheral Neuropathic Pain
CCR2 Antagonist
Type 2 Diabetes
BMS-936557 (Anti-IP-10 Antibody)
Crohn's Disease
Cyclosporine
Graft Rejection
BMS-986012 (anti-fucosyl-GM1)
Small Cell Lung Cancer
Irinotecan
Colorectal Cancer (CRC)
Thymoglobulin
Kidney Transplantation
BMS-986482
Advanced Solid Tumors
BMS-690514
Non-Small-Cell Lung Carcinoma
Belatacept
Renal Transplantation
Cyclosporine A
Renal Transplant
Ritonavir
HIV Infections
BMS-791325
Hepatitis C Virus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Temozolomide | Phase 3 | Brain Cancer | - | - |
Atazanavir/Ritonavir | Phase 3 | HIV | - | - |
Carboplatin | Phase 3 | Pediatric Solid Tumors | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - | - |
Mezigdomide | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Enoxaparin | Phase 3 | Deep Vein Thrombosis | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
Pegylated-Interferon-lambda | Phase 3 | Hepatitis C Virus | - | - |
Apixaban | Phase 3 | Lymphoma | - | - |
dasatinib | Phase 3 | Myeloid Leukemia, Chronic, Accelerated Phase | - | - |
Paclitaxel | Phase 3 | Breast Cancer | - | - |
Muraglitazar | Phase 3 | Metabolics Diabetes Nos | - | - |
Atazanavir + Ritonavir | Phase 3 | Human Immunodeficiency Virus (HIV) Infections | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Irbesartan monotherapy | Phase 3 | Hypertension | - | - |
Atazanavir Sulphate | Phase 3 | HIV | - | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - | - |
Asunaprevir (ASV) | Phase 3 | Hepatitis C Virus | - | - |
Antidepressant + Aripiprazole | Phase 3 | Major Depressive Disorder | - | - |
Asunaprevir | Phase 3 | Hepatitis C | - | - |
DCV | Phase 3 | Hepatitis C | - | - |
Relatlimab | Phase 3 | Advanced Gastric Cancer | - | - |
Daclatasvir | Phase 3 | Hepatitis C Infection | - | - |
Oral Azacitidine | Phase 3 | Myelodysplastic Syndromes | - | - |
Atazanavir (immediate switch) | Phase 3 | HIV Infections | - | - |
Cabozantinib | Phase 3 | Renal Cell Carcinoma | - | - |
Atazanavir | Phase 3 | HIV Infections | - | - |
Lamivudine/Zidovudine | Phase 3 | HIV Infections | - | - |
Peg-interferon Alfa-2a | Phase 3 | Hepatitis C Virus | - | - |
Gemcitabine | Phase 3 | Stage IV or Recurrent Non-Small Cell Lung Cancer | - | - |
Iza-bren | Phase 3 | Urothelial Cancer | - | - |
Bempegaldesleukin | Phase 3 | Bladder Cancer | - | - |
Pemetrexed | Phase 3 | Mesothelioma, Malignant | - | - |
Fluorouracil | Phase 3 | Various Advanced Cancer | - | - |
Xanomeline/Trospium Chloride Capsule | Phase 3 | Alzheimer Disease | - | - |
Iberdomide | Phase 3 | Multiple Myeloma | - | - |
Sunitinib | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
Deucravacitinib | Phase 3 | Psoriatic Arthritis | - | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Double-blind Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
BMS-986165 | Phase 3 | Psoriasis | - | - |
KarXT | Phase 3 | Alzheimer Disease | - | - |
BMS-790052 (NS5A Replication Complex Inhibitor) | Phase 3 | Hepatitis C | - | - |
DCV 3DAA | Phase 3 | Hepatitis C Virus Infection | - | - |
Atazanavir + ritonavir + tenofovir + nucleoside | Phase 3 | HIV Infections | - | - |
BMS-986504 | Phase 3 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | - | - |
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Phase 3 | Rheumatoid Arthritis | - | - |
BMS-936558 | Phase 3 | Unresectable or Metastatic Melanoma | - | - |
Videx EC | Phase 3 | HIV Infections | - | - |
Etoposide | Phase 3 | Small Cell Lung Carcinoma | - | - |
Apremilast | Phase 3 | Psoriatic Arthritis | - | - |
Ustekinumab | Phase 3 | Plaque Psoriasis | - | - |
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Phase 3 | Rheumatoid Arthritis | - | - |
Tenofovir | Phase 3 | Chronic Hepatitis B | - | - |
Oxaliplatin | Phase 3 | Colorectal Cancer | - | - |
Imatinib | Phase 3 | Chronic Myeloid Leukemia | - | - |
Telaprevir | Phase 3 | Hepatitis C | - | - |
MDX-010 (anti-CTLA4) monoclonal antibody | Phase 3 | Melanoma | - | - |
Paclitaxel and carboplatin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pegylated interferon lambda (pegIFNλ) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Prednisone | Phase 3 | Prostate Cancer | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
stavudine, efavirenz, lamivudine | Phase 3 | HIV Infections | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C Virus | - | - |
Subcutaneous (SC) Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Dacarbazine | Phase 3 | Melanoma | - | - |
Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Irbesartan/HCTZ | Phase 3 | Hypertension | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus (HCV) | - | - |
atazanavir/ritonavir +2 NRTIs (immediate Switch Group) | Phase 3 | HIV Infections | - | - |
Lenalidomide | Phase 3 | Multiple Myeloma | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Tanespimycin | Phase 3 | Advanced Malignancies | - | - |
Brivanib | Phase 3 | Hepato Cellular Carcinoma (HCC) | - | - |
BMS-986278 | Phase 3 | Idiopathic Pulmonary Fibrosis | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
Sorivudine | Phase 3 | HIV Infections | - | - |
KarX-EC | Phase 3 | Alzheimer's Disease | - | - |
warfarin | Phase 3 | Venous Thrombosis | - | - |
Adefovir | Phase 3 | Hepatitis B, Chronic | - | - |
Cyclosporin A | Phase 3 | Renal Transplantation | - | - |
Luspatercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Acetylsalicylic acid | Phase 3 | Atrial Fibrillation | - | - |
abatacept (ABA) | Phase 3 | Ulcerative Colitis | - | - |
pegIFNα-2b | Phase 3 | Hepatitis C Virus Infection | - | - |
Cetuximab | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
Mavacamten | Phase 3 | Cardiomyopathy, Hypertrophic | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Entecavir | Phase 3 | Hepatitis B, Chronic | - | - |
Cisplatin | Phase 3 | Non Small Cell Lung Cancer | - | - |
Vitamin K Antagonist (VKA) | Phase 2 | Thrombosis | - | - |
brivanib (active) | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
Letrozole | Phase 2 | Metastatic Breast Cancer | - | - |
CXL-1020 | Phase 2 | Heart Failure | - | - |
Abatacept (BMS-188667) | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986263 | Phase 2 | Hepatic Cirrhosis | - | - |
BMS-986490 | Phase 2 | Advanced Solid Tumors | - | - |
INX-08189 50 mg QD X 5 days | Phase 2 | Healthy | - | - |
MYK-491 | Phase 2 | Heart Failure With Reduced Ejection Fraction | - | - |
Anti-CD137 (4-1BB) (BMS-663513) | Phase 2 | Melanoma | - | - |
Sirolimus | Phase 2 | Disorder Related to Renal Transplantation | - | - |
BMS-914392 | Phase 2 | Atrial Fibrillation | - | - |
Erlotinib | Phase 2 | Non Small Cell Lung Cancer | - | - |
BMS-650032 | Phase 2 | Hepatitis C Virus | - | - |
bendamustine | Phase 2 | Hodgkin Disease | - | - |
nab-Paclitaxel | Phase 2 | Non-Small Cell Lung Cancer | - | - |
PSI-7977 | Phase 2 | Chronic Hepatitis C | - | - |
Pegylated Interferon Lambda | Phase 2 | Hepatitis C | - | - |
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC) | Phase 2 | HIV Infections | - | - |
200 mg INX-08189 Fasted | Phase 2 | Hepatitis C | - | - |
BMS-986369 | Phase 2 | Relapsed or Refractory T-cell Lymphomas | - | - |
unfractionated heparin (UFH) | Phase 2 | Antithrombotic | - | - |
Peginterferon alpha-2a | Phase 2 | Hepatitis C Infection | - | - |
MORAb-202 | Phase 2 | Neoplasms, Ovarian | - | - |
BMS-986523 | Phase 2 | Advanced Solid Malignancies | - | - |
BMS-986259 | Phase 2 | Acute Decompensated Heart Failure | - | - |
BMS-986036 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
branebrutinib | Phase 2 | Autoimmune Disorder | - | - |
Exemestane + Dasatinib | Phase 2 | Breast Cancer | - | - |
BMS-823778 | Phase 2 | Dyslipidemia | - | - |
Lirilumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
vinflunine | Phase 2 | Transitional Cell Carcinoma | - | - |
Dasatinib 100 mg | Phase 2 | Breast Cancer | - | - |
Duloxetine | Phase 2 | Depression | - | - |
MDX-1100 | Phase 2 | Rheumatoid Arthritis | - | - |
Fulvestrant | Phase 2 | Advanced Breast Cancer | - | - |
BMS-986213 | Phase 2 | Advanced Solid Tumors | - | - |
Trametinib | Phase 2 | Cancer | - | - |
Fedratinib | Phase 2 | Primary Myelofibrosis | - | - |
BMS-986158 | Phase 2 | Myelofibrosis | - | - |
BMS-986231 | Phase 2 | Cardiac Failure | - | - |
Megestrol acetate | Phase 2 | Anorexia | - | - |
BMS-986020 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Opdivo | Phase 2 | Renal Cell Carcinoma | - | - |
BMS-830216 | Phase 2 | Obesity | - | - |
carboplatin + irinotecan | Phase 2 | Neoplasms | - | - |
BMS-986340 | Phase 2 | Cervical Cancer | - | - |
Anastrozole | Phase 2 | Breast Cancer | - | - |
BMS-986446 | Phase 2 | Alzheimer Disease, Early Onset | - | - |
BMS-582949 | Phase 2 | Vascular Diseases | - | - |
Cobimetinib | Phase 2 | Microsatellite Unstable Colorectal Cancer | - | - |
MDX-010 | Phase 2 | Breast Cancer | - | - |
BMS-986004 75 mg IV | Phase 2 | Immune Thrombocytopenic Purpura | - | - |
SAR302503 (TG101348) | Phase 2 | Myelofibrosis | - | - |
Vemurafenib | Phase 2 | Melanoma | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986435 | Phase 2 | Heart Failure | - | - |
Afimetoran | Phase 2 | Systemic Lupus Erythematosus | - | - |
BMS-986205 | Phase 2 | Advanced Cancer | - | - |
ixabepilone | Phase 2 | Esophageal Cancer | - | - |
KOS-1584 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Thalidomide | Phase 2 | Relapsed and/or Refractory Multiple Myeloma | - | - |
INX-08189 50 mg | Phase 2 | Healthy | - | - |
Cyclophosphamide | Phase 2 | Breast Cancer | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986142 | Phase 2 | Rheumatoid Arthritis | - | - |
CC-92480 | Phase 2 | Multiple Myeloma | - | - |
BMS-770767 | Phase 2 | Diabetes Type 2 | - | - |
Pegylated-interferon alfa-2a | Phase 2 | Chronic Hepatitis C | - | - |
Cabiralizumab | Phase 2 | Advanced Pancreatic Cancer | - | - |
CXL-1427 | Phase 2 | Heart Failure | - | - |
Peginterferon α-2a | Phase 2 | Hepatitis C | - | - |
Aurexis® | Phase 2 | Staphylococcus Aureus Bacteremia | - | - |
BMS-986507 | Phase 2 | Lung Cancer | - | - |
Pegylated interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
BMS-954561 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
CCR2 Antagonist | Phase 2 | Type 2 Diabetes | - | - |
BMS-936557 (Anti-IP-10 Antibody) | Phase 2 | Crohn's Disease | - | - |
Cyclosporine | Phase 2 | Graft Rejection | - | - |
BMS-986012 (anti-fucosyl-GM1) | Phase 2 | Small Cell Lung Cancer | - | - |
Irinotecan | Phase 2 | Colorectal Cancer (CRC) | - | - |
Thymoglobulin | Phase 2 | Kidney Transplantation | - | - |
BMS-986482 | Phase 2 | Advanced Solid Tumors | - | - |
BMS-690514 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Belatacept | Phase 2 | Renal Transplantation | - | - |
Cyclosporine A | Phase 2 | Renal Transplant | - | - |
Ritonavir | Phase 2 | HIV Infections | - | - |
BMS-791325 | Phase 2 | Hepatitis C Virus | - | - |